Resources for AURYXIA

Find helpful resources, including videos, brochures, and more.

Mechanism of Action

Learn how the unique formulation of AURYXIA works in the body to help manage adult patients’ phosphorus levels.1,2

A Team Approach to Treating Hyperphosphatemia

Find out why these healthcare professionals choose AURYXIA for their adult patients with chronic kidney disease on dialysis.1

Access Support

Explore AURYXIA coverage for hyperphosphatemia.

Access SupportDOWNLOAD

AURYXIA Clinical Facts

Find out more about hyperphosphatemia and AURYXIA efficacy, safety, and access information.

AURYXIA Clinical FactsDOWNLOAD

AURYXIA Patient Handout

Help patients understand hyperphosphatemia and what to expect now that they have been prescribed AURYXIA.

AURYXIA Patient HandoutDOWNLOAD

Hyperphosphatemia Patient Handout

Give patients the important facts about hyperphosphatemia, why it should be managed, tips for controlling their phosphorus levels, and more.

AURYXIA Patient HandoutDOWNLOAD

Patient Nutrition Handout

Help patients understand where phosphorus appears in their meals and how to read nutrition fact labels to find hidden phosphorus in food.

AURYXIA Patient HandoutDOWNLOAD

IMPORTANT SAFETY INFORMATION AND INDICATION

CONTRAINDICATION

AURYXIA® (ferric citrate) is contraindicated in patients with iron overload syndromes, e.g., hemochromatosis

WARNINGS AND PRECAUTIONS

  • Iron Overload: Increases in serum ferritin and transferrin saturation (TSAT) were observed in clinical trials with AURYXIA in patients with chronic kidney disease (CKD) on dialysis treated for hyperphosphatemia, which may lead to excessive elevations in iron stores. Assess iron parameters prior to initiating AURYXIA and monitor while on therapy. Patients receiving concomitant intravenous (IV) iron may require a reduction in dose or discontinuation of IV iron therapy
  • Risk of Overdosage in Children Due to Accidental Ingestion: Accidental ingestion and resulting overdose of iron-containing products is a leading cause of fatal poisoning in children under 6 years of age. Advise patients of the risks to children and to keep AURYXIA out of the reach of children

ADVERSE REACTIONS
The most common adverse reactions reported with AURYXIA in clinical trials were:

  • Hyperphosphatemia in CKD on Dialysis: Diarrhea (21%), discolored feces (19%), nausea (11%), constipation (8%), vomiting (7%) and cough (6%)

SPECIFIC POPULATIONS

  • Pregnancy and Lactation: There are no available data on AURYXIA use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. However, an overdose of iron in pregnant women may carry a risk for spontaneous abortion, gestational diabetes and fetal malformation. Data from rat studies have shown the transfer of iron into milk, hence, there is a possibility of infant exposure when AURYXIA is administered to a nursing woman

INDICATION

AURYXIA® (ferric citrate) is indicated for:

  • The control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis

To report suspected adverse reactions, contact Akebia Therapeutics, Inc. at 1-844-445-3799

Please see full Prescribing Information

REFERENCES

  1. AURYXIA [package insert]. Cambridge, MA: Akebia Therapeutics, Inc.; 2021.
  2. Ganz T, Bino A, Salusky IB. Mechanism of Action and Clinical Attributes of Auryxia® (Ferric Citrate). Drugs. 2019;79(9):957-968.
  3. Data on File 29, Akebia Therapeutics, Inc.
  4. Data on File 30, Akebia Therapeutics, Inc.